Drug Efficacy Articles & Analysis: Older
44 news found
Watertown, MA — October 24, 2024 — Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical ...
CD ComputaBio, a pioneering provider of computational biology services, has recently introduced its advanced Computer-Aided Drug Design (CADD) services, revolutionizing the drug discovery landscape. ...
CD Formulation, an expert in the pharmaceutical research and development field, has announced the expansion of its comprehensive pharmacological services to support the burgeoning sector of veterinary drugs. The move is poised to elevate the standard and efficacy of veterinary pharmaceuticals, reinforcing CD Formulation’s dedication to the well-being of ...
CD Formulation is making waves in the pharmaceutical industry with its innovative drug delivery technologies. With a focus on sustained and controlled release formulations, as well as liquid, semi-solid, injectable, and nanoformulations, CD Formulation is at the forefront of the industry's efforts to enhance drug efficacy. ...
Typically, the structures of such polymers are designed to reduce their dispersion in solution, thereby improving their stability and controllability. They’re widely used as drug carriers mainly because of their ability to efficiently carry and release drug molecules, thereby improving drug bioavailability and therapeutic ...
This accuracy reduces the risk of over or under-dosing and improves therapeutic outcomes. The advantages of this drug delivery system extend beyond patient convenience and precise dosing, as the technology also enhances the bioavailability of drugs. ...
In the field of pharmaceutical formulation, stability analysis is a critical aspect that ensures the safety and efficacy of drugs throughout their shelf life. CD formulation has introduced a series of stability analysis services as a prominent tool for researchers to understand the influence of various factors and tests on the stability of pharmaceutical ...
In the ever-evolving field of pharmaceuticals, CD Formulation has emerged as a major player in developing innovative drug delivery systems aimed at enhancing the efficacy and safety of therapies. ...
CD Formulation, a leading pharmaceutical research and development company, has recently unveiled a series of cutting-edge technologies that will further revolutionize and redefine the realm of drug delivery. “With a focus on microspheres, microneedles and microencapsulation, we aim to improve the efficacy and convenience of drug delivery ...
For Biomedical research, R-PE labeled proteins can be used as fluorescent probes for drug efficacy, biological molecular components, biomarker and diagnostic and therapeutic methods. In Clinical trials, R-PE labeled proteins can be used for dynamic monitoring of drugs and pharmacokinetic studies. With a complete, professional, as well as an ...
The service predicts key parameters such as the interaction modes between molecules, including hydrogen bonds, van der Waals forces, and ionic bonds, as well as binding affinity and complementarity, to help clients better understand the mechanism of drug action and optimize drug molecule design and screening. Small molecule drug development ...
IVS offers services using the LITATM for testing efficacy and safety of drug candidates. The LITATM will be available soon for in-house operations at customers’ sites. ...
The high failure rate of cardiovascular clinical trials (e.g., 11% of Phase II failure between 2008-11) indicates that there is an unmet need for more focused approaches, including personalized drug discovery for specific patient groups or even for rare genetic diseases, i.e., orphan drug market. Cardiovascular safety liabilities remain the major cause of costly ...
VeriSIM Life has developed a whole-body biosimulation platform driven by AI and machine learning (ML), that accurately predicts the clinical efficacy of new drugs before human trials. We are delivering strategic insights from our platform to translate, scale, and accelerate drug development to advance human health. ...
Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on supporting Computer Aided Drug Design, Thermodynamic Calculation, Fluorescence Spectrum Prediction, and applications that accelerate novel drug ...
Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening. Drug efficacy and toxicity ...
These results solve the critical issue of CTC rarity and pave the way for their use in early diagnostics of cancer, prognostics, theranostics, and in vitro personalized drug efficacy tests, including through CTC culture. “With the ISET technology, we were able to effectively extract CTC in higher numbers and from larger DLA volumes, in all cases thus ...
The implication of this precise control is the maintenance of adequate and efficacious drug levels over the entire dosage interval. Starton’s previous in vivo studies demonstrated superior efficacy with continuous SC administration compared to once daily dosing in a multiple myeloma model. The maximum effective dose was 71% lower than the ...
“We are excited to expand our common mission and work with the world’s top research hospital and its drug discovery programs.” Under the terms of the collaboration agreement, VeriSIM will leverage its proprietary BIOiSIM™ platform and Translational Index™ approach to reduce the number of outsourced preclinical experiments and help de-risk R&D ...
The approval of Aikening® is based on the pivotal phase 3 TALENT (Test Albuvirtide in Experienced Patients), which demonstrated that an albuvirtide-based two-drug treatment arm was non-inferior to a lopinavir (LPV)-based three-drug arm (75.7% vs 77.3%). The results showed successful achievement of the primary endpoint, with a good proportion of patients on ...